Huazhong University of Science and Technology
hust.edu.cnTotal trials
239
Active
58
Phase 3
14
Total enrollment
4,819,477
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Bupivacaine | — | — | — | — | — | 2 | |
| Iparomlimab and Tuvonralimab | — | — | — | — | 2 | ||
| Tirzepatide | — | — | — | — | — | 1 | |
| Bupivacaine Liposomes | — | — | — | — | — | 1 | |
| Intravenous Ketamine Infusions | — | — | — | — | — | 1 | |
| Intravenous normal saline | — | — | — | — | — | 1 | |
| Oral Duloxetine 60mg | — | — | — | — | — | 1 | |
| Liposomal bupivacaine plus bupivacaine | — | — | — | — | — | 1 | |
| Bupivacaine liposome | — | — | — | — | — | 1 | |
| Group A（ liposomal bupivacene） | — | — | — | — | — | 1 | |
| Group B（bupivacene） | — | — | — | — | — | 1 | |
| SGLT2i+Metformin+Cofrogliptin | — | — | — | — | — | 1 | |
| SGLT2i+Metformin+Linagliptin | — | — | — | — | — | 1 | |
| Ropivacaine | — | — | — | — | 4 | ||
| Adjuvant chemotherapy | — | — | — | — | — | 2 | |
| Paclitaxel or docetaxel + Cisplatin or carboplatin | — | — | — | — | — | 1 | |
| Fruquintinib | — | — | — | — | — | 2 | |
| Camrelizumab | — | — | — | — | — | 3 | |
| Fluzoparib | — | — | — | — | — | 1 | |
| CAPEOX | — | — | — | — | — | 1 | |
| Cadonilimab | — | — | — | — | — | 1 | |
| Zanubrutinib plus RCHOP | — | — | — | — | — | 1 | |
| Cisplatin+Albumin-bound paclitaxel | — | — | — | — | — | 1 | |
| Vitamin D3 | — | — | — | — | — | 3 | |
| Anesthetic Agents | — | — | — | — | — | 1 | |
| Calculus bovis sativus | — | — | — | — | — | 1 | |
| Liposomal bupivacaine | — | — | — | — | — | 1 | |
| Ropivacaine with Perineural Dexamethasone | — | — | — | — | — | 1 | |
| Ropivacaine with Perineural Dexmedetomidine | — | — | — | — | — | 1 | |
| Stapokibart | — | — | — | — | — | 1 |
Next readouts
- 2023-04-30
- 2025-06-28
- 2025-12-31
- 2026-01-31
- 2026-02-01
- 2026-02-28
- 2026-03-31
- 2026-04-01
- 2026-06-01
- 2026-07
Top conditions
- Cervical Cancer15
- Gastric Cancer7
- Uterine Cervical Cancer5
- Uterine Cervical Neoplasm4
- Delirium4
- Uterine Cervical Neoplasms4
- Postoperative Death4
- Hepatocellular Carcinoma4
Frequently asked questions about Huazhong University of Science and Technology
- How many clinical trials does Huazhong University of Science and Technology have on ClinicalTrials.gov?
- Huazhong University of Science and Technology is listed as the lead sponsor on 239 clinical trials in ClinicalTrials.gov, 58 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Huazhong University of Science and Technology's trials are in Phase 3?
- 14 of Huazhong University of Science and Technology's trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does Huazhong University of Science and Technology focus on?
- Huazhong University of Science and Technology's most-studied conditions on ClinicalTrials.gov are Cervical Cancer, Gastric Cancer, Uterine Cervical Cancer, Uterine Cervical Neoplasm, Delirium.
- When are Huazhong University of Science and Technology's next clinical trial readouts?
- Huazhong University of Science and Technology has 10 upcoming primary-completion readouts tracked here; the soonest is “Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer”, expected around 2023-04-30.